Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    Jorge Cortes 2013


    Professor Jorge Cortes
    Georgia Cancer Centre, Augusta (USA)

    Overview of significant clinical aspects presented during the meeting, including:

    • Update on the iCMLf CANDID study - COVID-19 in patients with CML
    • Treatment-free remission
      • Final report of the EURO-SKI study
      • Interim results of the Russian Prospective Study of Reduction and Discontinuation of TKI
      • Mathematical modeling on risk of relapses and withdrawal syndrom
    • Updates on clinical studies
      • Final report of the BYOND study (bosutinib in previously treated patients)
      • Primary analysis of the OPTIC trial (Dose-optimization study of 3 starting doses of ponatinib)
      • Post-hoc analysis of DASISION: Effect of comorbidities on response outcomes:
      • Updated results of Phase 1 study with new agent vodobatinib
    • Incidence of pleural effusions with dasatinb and effect of switching to bosutinib

    Q&A Session